Objectives: This double-blind trial evaluated the efficacy and safety of abatacept or infliximab
vs placebo. The primary objective of this study was to evaluate the mean change from …

Objective: To assess the safety, tolerability and efficacy of abatacept in patients with
rheumatoid arthritis (RA) who had failed anti-tumour necrosis factor (TNF) therapy and were …

Objective To evaluate abatacept treatment over 3 years in patients with rheumatoid arthritis
(RA) refractory to methotrexate (MTX). Methods Patients randomised to abatacept or …

Objectives To compare over 2 years the safety, efficacy and radiographic outcomes of
subcutaneous abatacept versus adalimumab, in combination with methotrexate (MTX), in …

Objective. To perform a systematic review of efficacy and safety of abatacept in patients with
rheumatoid arthritis (RA). Methods. We searched the Cochrane Library, MEDLINE …

Objectives To evaluate clinical remission with subcutaneous abatacept plus methotrexate
(MTX) and abatacept monotherapy at 12 months in patients with early rheumatoid arthritis …

Objectives: To assess the efficacy and safety of abatacept in methotrexate-naive patients
with early rheumatoid arthritis (RA) and poor prognostic factors. Methods: In this double …

Background: The selective co-stimulation modulator abatacept demonstrated efficacy for
treating rheumatoid arthritis in early clinical studies. Objective: To evaluate the effects of …

The biological DMARD (bDMARD) abatacept (Orencia®), a recombinant fusion protein,
selectively modulates a co-stimulatory signal necessary for T-cell activation. In the EU …

Background A substantial number of patients with rheumatoid arthritis have an inadequate
or unsustained response to tumor necrosis factor α (TNF-α) inhibitors. We conducted a …